Oncology Drug Trends
HealthLeaders magazine, November 13, 2013
Cancer patients may have a different point of view on oncology drug decisions than nonpatients, according to a survey conducted by Truven Health Analytics. Healthcare consumers were asked whether they agreed or disagreed with a recent decision by a large cancer center to not offer a new medication that has similar benefits and side effects as an existing drug but is more costly. The fact that those who have had the most experience with cancer were the most likely to agree with the cancer center's decision suggests that those who have experienced both the benefits and side effects of cancer drugs, and possibly out-of-pocket costs for these medications, may have more realistic attitudes toward cancer treatments.